Advertisement
Screener

OCULAR THERAPEUTIX, INC (OCUL) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

OCULAR THERAPEUTIX, INC Operating Cash Flow

OCULAR THERAPEUTIX, INC (OCUL) reported Operating Cash Flow of -$133.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03

  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$67.27M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$65.99M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$54.25M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$50.73M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for fiscal 2025 was -$204.88M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for fiscal 2024 was -$134.68M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for fiscal 2023 was -$70.23M.
  • OCULAR THERAPEUTIX, INC net cash provided by (used in) operating activities for fiscal 2022 was -$59.60M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$67.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
-$133.26M
10-Q · filed 2026-08-03
-$187.51M
derived: sum of 3 quarters · filed 2026-08-03
-$238.24M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31-$65.99M
10-Q · filed 2026-05-05
-$120.24M
derived: sum of 2 quarters · filed 2026-05-05
-$170.97M
derived: sum of 3 quarters · filed 2026-05-05
-$226.21M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31-$54.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05
-$104.97M
derived: sum of 2 quarters · filed 2026-02-05
-$160.21M
derived: sum of 3 quarters · filed 2026-08-03
-$204.88M
10-K · filed 2026-02-05
2025-09-30-$50.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$105.96M
derived: sum of 2 quarters · filed 2026-08-03
-$150.63M
10-Q · filed 2025-11-04
-$190.06M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30-$55.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
-$99.91M
10-Q · filed 2026-08-03
-$139.34M
derived: sum of 3 quarters · filed 2026-08-03
-$175.90M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31-$44.67M
10-Q · filed 2026-05-05
-$84.10M
derived: sum of 2 quarters · filed 2026-05-05
-$120.66M
derived: sum of 3 quarters · filed 2026-05-05
-$145.46M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$39.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05
-$75.99M
derived: sum of 2 quarters · filed 2026-02-05
-$100.79M
derived: sum of 3 quarters · filed 2026-02-05
-$134.68M
10-K · filed 2026-02-05
2024-09-30-$36.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$61.36M
derived: sum of 2 quarters · filed 2025-11-04
-$95.25M
10-Q · filed 2025-11-04
-$117.70M
derived: sum of 4 quarters · filed 2026-02-05
2024-06-30-$24.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$58.69M
10-Q · filed 2025-08-05
-$81.14M
derived: sum of 3 quarters · filed 2026-02-05
-$88.88M
derived: sum of 4 quarters · filed 2026-02-05
2024-03-31-$33.89M
10-Q · filed 2025-05-05
-$56.34M
derived: sum of 2 quarters · filed 2026-02-05
-$64.07M
derived: sum of 3 quarters · filed 2026-02-05
-$84.15M
derived: sum of 4 quarters · filed 2026-02-05
2023-12-31-$22.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05
-$30.19M
derived: sum of 2 quarters · filed 2026-02-05
-$50.26M
derived: sum of 3 quarters · filed 2026-02-05
-$70.23M
10-K · filed 2026-02-05
2023-09-30-$7.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$27.81M
derived: sum of 2 quarters · filed 2024-11-14
-$47.78M
10-Q · filed 2024-11-14
-$64.74M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30-$20.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
-$40.05M
10-Q · filed 2024-08-07
-$57.01M
derived: sum of 3 quarters · filed 2025-03-03
-$70.17M
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31-$19.97M
10-Q · filed 2024-05-07
-$36.93M
derived: sum of 2 quarters · filed 2025-03-03
-$50.10M
derived: sum of 3 quarters · filed 2025-03-03
-$60.98M
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31-$16.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
-$30.13M
derived: sum of 2 quarters · filed 2025-03-03
-$41.00M
derived: sum of 3 quarters · filed 2025-03-03
-$59.60M
10-K · filed 2025-03-03
2022-09-30-$13.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$24.05M
derived: sum of 2 quarters · filed 2023-11-07
-$42.65M
10-Q · filed 2023-11-07
-$57.80M
derived: sum of 4 quarters · filed 2024-03-11
2022-06-30-$10.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
-$29.48M
10-Q · filed 2023-08-07
-$44.63M
derived: sum of 3 quarters · filed 2024-03-11
-$57.61M
derived: sum of 4 quarters · filed 2024-03-11
2022-03-31-$18.60M
10-Q · filed 2023-05-08
-$33.75M
derived: sum of 2 quarters · filed 2024-03-11
-$46.73M
derived: sum of 3 quarters · filed 2024-03-11
-$66.79M
derived: sum of 4 quarters · filed 2024-03-11
2021-12-31-$15.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11
-$28.14M
derived: sum of 2 quarters · filed 2024-03-11
-$48.19M
derived: sum of 3 quarters · filed 2024-03-11
-$65.55M
10-K · filed 2024-03-11
2021-09-30-$12.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$33.04M
derived: sum of 2 quarters · filed 2022-11-07
-$50.40M
10-Q · filed 2022-11-07
-$56.64M
derived: sum of 4 quarters · filed 2023-03-06
2021-06-30-$20.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$37.41M
10-Q · filed 2022-08-08
-$43.66M
derived: sum of 3 quarters · filed 2023-03-06
-$57.32M
derived: sum of 4 quarters · filed 2023-03-06
2021-03-31-$17.36M
10-Q · filed 2022-05-09
-$23.61M
derived: sum of 2 quarters · filed 2023-03-06
-$37.26M
derived: sum of 3 quarters · filed 2023-03-06
-$52.06M
derived: sum of 4 quarters · filed 2023-03-06
2020-12-31-$6.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06
-$19.90M
derived: sum of 2 quarters · filed 2023-03-06
-$34.70M
derived: sum of 3 quarters · filed 2023-03-06
-$53.55M
10-K · filed 2023-03-06
2020-09-30-$13.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$28.45M
derived: sum of 2 quarters · filed 2021-11-08
-$47.31M
10-Q · filed 2021-11-08
-$66.78M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$14.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$33.65M
10-Q · filed 2021-08-09
-$53.12M
derived: sum of 3 quarters · filed 2022-02-28
-$72.66M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31-$18.85M
10-Q · filed 2021-05-05
-$38.32M
derived: sum of 2 quarters · filed 2022-02-28
-$57.87M
derived: sum of 3 quarters · filed 2022-02-28
-$77.05M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31-$19.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$39.01M
derived: sum of 2 quarters · filed 2022-02-28
-$58.19M
derived: sum of 3 quarters · filed 2022-02-28
-$77.58M
10-K · filed 2022-02-28
2019-09-30-$19.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$38.73M
derived: sum of 2 quarters · filed 2020-11-05
-$58.11M
10-Q · filed 2020-11-05
-$71.76M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$19.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
-$38.57M
10-Q · filed 2020-08-07
-$52.22M
derived: sum of 3 quarters · filed 2020-08-07
-$63.09M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31-$19.39M
10-Q · filed 2020-05-08
-$33.03M
derived: sum of 2 quarters · filed 2020-05-08
-$43.91M
derived: sum of 3 quarters · filed 2020-05-08
-$56.14M
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31-$13.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$24.52M
derived: sum of 2 quarters · filed 2020-03-12
-$36.75M
derived: sum of 3 quarters · filed 2020-03-12
-$49.23M
10-K · filed 2020-03-12
2018-09-30-$10.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$23.11M
derived: sum of 2 quarters · filed 2019-11-12
-$35.58M
10-Q · filed 2019-11-12
-$45.96M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30-$12.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$24.71M
10-Q · filed 2019-08-07
-$35.09M
derived: sum of 3 quarters · filed 2020-03-12
-$49.47M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31-$12.47M
10-Q · filed 2019-05-10
-$22.86M
derived: sum of 2 quarters · filed 2020-03-12
-$37.24M
derived: sum of 3 quarters · filed 2020-03-12
-$48.37M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31-$10.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$24.77M
derived: sum of 2 quarters · filed 2020-03-12
-$35.90M
derived: sum of 3 quarters · filed 2020-03-12
-$50.47M
10-K · filed 2020-03-12
2017-09-30-$14.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$25.51M
derived: sum of 2 quarters · filed 2018-11-07
-$40.09M
10-Q · filed 2018-11-07
-$47.70M
derived: sum of 4 quarters · filed 2019-03-07
2017-06-30-$11.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
-$25.71M
10-Q · filed 2018-08-07
-$33.32M
derived: sum of 3 quarters · filed 2019-03-07
-$40.65M
derived: sum of 4 quarters · filed 2019-03-07
2017-03-31-$14.58M
10-Q · filed 2018-05-08
-$22.19M
derived: sum of 2 quarters · filed 2019-03-07
-$29.52M
derived: sum of 3 quarters · filed 2019-03-07
2016-12-31-$7.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
-$14.94M
derived: sum of 2 quarters · filed 2019-03-07
-$34.00M
10-K · filed 2019-03-07
2016-09-30-$7.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
-$26.39M
10-Q · filed 2017-11-07
2016-06-30-$19.06M
10-Q · filed 2017-08-08
2015-12-31-$33.74M
10-K · filed 2018-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Zai Lab Ltd (ZLAB)$2.241B-113.34
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05